A company paying $80m up front to license a preclinical asset can turn heads, but Novartis AG is committing that much for Pliant Therapeutics Inc.’s integrin inhibitor PLN-1474 for two reasons – it adds a drug with an anti-fibrotic mechanism to its portfolio of non-alcoholic steatohepatitis (NASH) candidates, and the drug’s preclinical development included head-to-head testing with other NASH candidates in human liver tissue from transplant patients.
South San Francisco-based Pliant announced before the markets opened on 23 October that it will get $80m up front –...








